Print this article
Two fines for UBS
Chris Hamblin
18 November 2019
The two regulators levied their fines within three days of each other. On 11 November came the Hong Kong fine, with the SFC alleging that the Swiss wealth management giant not only failed to observe the fundamental and overarching duty to act in its clients’ best interests but also abused the trust of unsuspecting clients by failing to tell them about conflicts of interest and by overcharging them in opaque trades. The statement of disciplinary action reads: "Between 2008 and 2017, UBS overcharged its clients by increasing the spread after execution of trades without their knowledge and charging them fees in excess of standard disclosures or rates. The overcharge amounted to approximately HK$180 million, affecting about Hong Kong-managed 5,000 client accounts in about 28,700 transactions." Between 2008 and 2015, it was a widespread practice for the client advisors (CAs) and client advisors’ assistants (CAAs) in UBS’s wealth management division to increase the spread charged to clients after the execution of a trade (post-trade spread increase or PTSI) in bonds and structured notes. The details are as follows. In Hong Kong UBS is registered under the Securities and Futures Ordinance to do business in Type 1 (dealing in securities), Type 4 (advising on securities), Type 6 (advising on corporate finance), Type 7 (providing automated trading services) and Type 9 (asset management) regulated activities. The SFC says that UBS failed to: In Singapore, where US$1 = S$1.36, UBS has admitted liability for its client advisors' actions, paid the regulator the civil penalty and promised to compensate all affected clients of its Singapore branch. When UBS executed over-the-counter (OTC) transactions requested by its clients, it did so with interbank counterparties, and its practice was to charge a spread over the interbank price that it obtained from the counterparty. The actions of its client advisors regarding the spreads and/or interbank prices for transactions in OTC bonds and structured products were potentially deceitful. UBS itself reported the misconduct to the MAS in 2016, prompting investigations. The MAS says that its investigations showed that in numerous transactions the client advisors either: